METHODS AND SYSTEMS FOR SPATIALLY IDENTIFYING ABNORMAL CELLS
The present invention provides compositions and methods for imaging tumor resections.
1 . An method for spatially determining tissue heterogeneity in a subject undergoing surgery or a minimally invasive intervention, the method comprising:
(a) administering a composition comprising a molecular imaging probe to said subject; and
(b) obtaining an in situ image of said tissue wherein the image allows for the detection of a diseased cell, if present in said tissue.
2 . A method of tumor resection comprising:
(a) administering a composition comprising a molecular imaging probe to a tissue of a subject undergoing surgery or a minimally invasive intervention;
(b) obtaining an in situ image of said tissue wherein the image allows for the detection of a diseased cell, if present in the tissue
(c) removing said diseased cell detected in step (b)
(d) repeating steps (b) and step (c) until no diseased cell is detected in said tissue.
3 . A method of confirming the surgical margin of an excised tumor or growth comprising;
(a) topically administering a composition comprising a molecular imaging probe to the surface of the excised tumor or growth;
(b) obtaining an in situ image of said tumor or growth wherein the image allows for the detection of a diseased cell, if present in the tissue.
4 . The method of claim 1 , wherein said composition is administered systemically to said subject or topically to said tissue.
5 . The method of claim 3 , wherein said topical administration is by spraying or painting.
6 . The method of claim 1 , wherein said composition is administered on a film or sponge.
8 . The method of claim 1 , wherein said diseases cell is a tumor cell.
9 . The method of claims 1 , wherein said molecular imaging probe comprising a targeting moiety and an imaging moiety.
10 . The method of claim 9 , wherein said imaging moiety is a chromophore, a fluorochrome or a chemoluminescent moiety.
11 . The method of claim 10 , wherein said fluorochrome is a near infrared fluorochrome.
12 . The method of claim 11 , wherein said near infrared fluorochrome is Cy5.5, Cy5, Cy 7, Alexa, Fluoro 680, Alexa Fluoro 750, IRD41, IRD700, NIR-1, LaJolla Blue, indocyanine green (ICG), indotricarbocyanine (ITC), or a chelated lanthanide compound.
13 . The method of claim 10 , wherein said chemoluminescent moiety is a bioluminescent moiety.
12 . The method of claim 10 , wherein said bioluminescent moiety is a combination of luciference and luciferin, Guassia luciferase and colenterazine, or luminol and peroxide.
13 . The method of claim 9 , wherein said targeting moiety binds specifically to CD20, CD33, carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), CA125, CA19-9, prostate specific antigen (PSA), human chorionic gonadotropin (HCG), acid phosphatase, neuron specific enolase, galacatosyl transferase II, immunoglobulin, CD326, her2NEU, EGFR, PSMA, TTF1, Muc, immature glycoslytaion, or an EMT marker.
14 . The method according to claim 1 , wherein the composition further comprises a UV dye or a fluorescent compound.
15 . The method according claim 1 , wherein the composition further comprises a compound which alters the osmotic pressure at the site of administration.
16 . The method according to claim 1 , wherein the composition further comprises a compound which alters the pH, or ionic strength at the site of administration.
17 . The method according to claim 1 , wherein the molecular imaging probe is actvated by the tumor.
18 . The method according to claim 1 , wherein the molecular imaging probe diffuses into the tissue in less than 5 minutes after topical administration.